Limits...
Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer.

Torkelson CJ, Sweet E, Martzen MR, Sasagawa M, Wenner CA, Gay J, Putiri A, Standish LJ - ISRN Oncol (2012)

Bottom Line: Nine adverse events were reported (7 mild, 1 moderate, and 1 severe), suggesting that Tv was well tolerated.Immunological results indicated trends in (1) increased lymphocyte counts at 6 and 9 grams/day; (2) increased natural killer cell functional activity at 6 grams/day; (3) dose-related increases in CD8(+) T cells and CD19(+) B cells , but not CD4(+) T cells or CD16(+)56(+) NK cells.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Family Medicine and Community Health, Medical School, University of Minnesota, 420 Delaware Street SE, MMC 381, Mayo Building B529, Minneapolis, MN 55455, USA.

ABSTRACT
Introduction. Orally administered preparations from the Trametes versicolor (Tv) mushroom have been hypothesized to improve immune response in women with breast cancer after standard chemotherapy and radiotherapy. Methods. A phase I, two-center, dose escalation study was done to determine the maximum tolerated dose of a Tv preparation when taken daily in divided doses for 6 weeks after recent completion of radiotherapy. Eleven participants were recruited and nine women completed the study. Each cohort was comprised of three participants given one of three doses of Tv (3, 6, or 9 grams). Immune data was collected pre- and postradiation, at 3 on-treatment time points and after a 3-week washout. Results. Nine adverse events were reported (7 mild, 1 moderate, and 1 severe), suggesting that Tv was well tolerated. Immunological results indicated trends in (1) increased lymphocyte counts at 6 and 9 grams/day; (2) increased natural killer cell functional activity at 6 grams/day; (3) dose-related increases in CD8(+) T cells and CD19(+) B cells , but not CD4(+) T cells or CD16(+)56(+) NK cells. Conclusion. These findings show that up to 9 grams/day of a Tv preparation is safe and tolerable in women with breast cancer in the postprimary treatment setting. This Tv preparation may improve immune status in immunocompromised breast cancer patients following standard primary oncologic treatment.

No MeSH data available.


Related in: MedlinePlus

© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3369477&req=5

Mentions: According to the composite scores of eight dose escalation participants, radiotherapy did not significantly alter the B cell count (Figure 5). However Tv administration was associated with an increase in CD19+ B cells. One-way ANOVA was used to analyze the overall difference between dosage groups over the treatment period (2–4–6 weeks). It showed the statistically significant increase in CD19+ B cells for the 6 g dose group compared to the 3 g group [F(2, 6) = 6.312, P = 0.0334]. The difference between the 3 g and 9 g groups and also the 6 g and 9 g groups was not significant (see Figure 5).


Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer.

Torkelson CJ, Sweet E, Martzen MR, Sasagawa M, Wenner CA, Gay J, Putiri A, Standish LJ - ISRN Oncol (2012)

© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3369477&req=5

Mentions: According to the composite scores of eight dose escalation participants, radiotherapy did not significantly alter the B cell count (Figure 5). However Tv administration was associated with an increase in CD19+ B cells. One-way ANOVA was used to analyze the overall difference between dosage groups over the treatment period (2–4–6 weeks). It showed the statistically significant increase in CD19+ B cells for the 6 g dose group compared to the 3 g group [F(2, 6) = 6.312, P = 0.0334]. The difference between the 3 g and 9 g groups and also the 6 g and 9 g groups was not significant (see Figure 5).

Bottom Line: Nine adverse events were reported (7 mild, 1 moderate, and 1 severe), suggesting that Tv was well tolerated.Immunological results indicated trends in (1) increased lymphocyte counts at 6 and 9 grams/day; (2) increased natural killer cell functional activity at 6 grams/day; (3) dose-related increases in CD8(+) T cells and CD19(+) B cells , but not CD4(+) T cells or CD16(+)56(+) NK cells.Conclusion.

View Article: PubMed Central - PubMed

Affiliation: Department of Family Medicine and Community Health, Medical School, University of Minnesota, 420 Delaware Street SE, MMC 381, Mayo Building B529, Minneapolis, MN 55455, USA.

ABSTRACT
Introduction. Orally administered preparations from the Trametes versicolor (Tv) mushroom have been hypothesized to improve immune response in women with breast cancer after standard chemotherapy and radiotherapy. Methods. A phase I, two-center, dose escalation study was done to determine the maximum tolerated dose of a Tv preparation when taken daily in divided doses for 6 weeks after recent completion of radiotherapy. Eleven participants were recruited and nine women completed the study. Each cohort was comprised of three participants given one of three doses of Tv (3, 6, or 9 grams). Immune data was collected pre- and postradiation, at 3 on-treatment time points and after a 3-week washout. Results. Nine adverse events were reported (7 mild, 1 moderate, and 1 severe), suggesting that Tv was well tolerated. Immunological results indicated trends in (1) increased lymphocyte counts at 6 and 9 grams/day; (2) increased natural killer cell functional activity at 6 grams/day; (3) dose-related increases in CD8(+) T cells and CD19(+) B cells , but not CD4(+) T cells or CD16(+)56(+) NK cells. Conclusion. These findings show that up to 9 grams/day of a Tv preparation is safe and tolerable in women with breast cancer in the postprimary treatment setting. This Tv preparation may improve immune status in immunocompromised breast cancer patients following standard primary oncologic treatment.

No MeSH data available.


Related in: MedlinePlus